|
|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
149,990,000 |
Market
Cap: |
137.98(M) |
Last
Volume: |
394,168 |
Avg
Vol: |
198,527 |
52
Week Range: |
$0.9199 - $0.9199 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Lineage Cell Therapeutics is a clinical-stage biotechnology company developing cell therapies. Co. has several allogeneic cell therapy programs in development: OpRegen®, a retinal pigment epithelium cell replacement therapy for the treatment of advanced dry age-related macular degeneration with geographic atrophy; OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injuries; VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells; and other product candidates in preclinical development covering a range of therapeutic areas and target tissues or organs. Co. has rights to HyStem, a patented biomaterial that mimics naturally occurring extracellular matrix.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
7,894,737 |
8,015,237 |
14,862,162 |
Total Buy Value |
$0 |
$6,000,000 |
$6,073,835 |
$13,195,237 |
Total People Bought |
0 |
1 |
5 |
7 |
Total Buy Transactions |
0 |
2 |
7 |
12 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Samuel George A. Iii |
General Counsel |
|
2025-02-11 |
4 |
D |
$0.65 |
$1,586 |
D/D |
(2,440) |
25,820 |
|
- |
|
Samuel George A. Iii |
General Counsel |
|
2025-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,076 |
28,260 |
|
- |
|
Culley Brian M |
President and CEO |
|
2025-02-11 |
4 |
D |
$0.65 |
$8,156 |
D/D |
(12,547) |
213,544 |
|
- |
|
Culley Brian M |
President and CEO |
|
2025-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,249 |
226,091 |
|
- |
|
Bradsher Neal C |
Director |
|
2025-01-27 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
49,560,992 |
2.17 |
- |
|
Bradsher Neal C |
Director |
|
2025-01-27 |
4 |
B |
$0.76 |
$6,000,000 |
D/D |
7,894,737 |
49,560,992 |
3.92 |
- |
|
Howe Jill Ann |
Chief Financial Officer |
|
2024-11-26 |
4 |
B |
$0.59 |
$8,850 |
D/D |
15,000 |
25,500 |
0.01 |
- |
|
Samuel George A. Iii |
General Counsel |
|
2024-11-26 |
4 |
B |
$0.60 |
$9,000 |
D/D |
15,000 |
22,184 |
0.01 |
- |
|
Mulroy Michael H. |
|
|
2024-11-22 |
4 |
B |
$0.57 |
$22,640 |
D/D |
40,000 |
298,555 |
0.01 |
- |
|
Culley Brian M |
President and CEO |
|
2024-11-21 |
4 |
B |
$0.60 |
$24,000 |
D/D |
40,000 |
194,842 |
0.01 |
- |
|
Howe Jill Ann |
Chief Financial Officer |
|
2024-08-16 |
4 |
B |
$0.89 |
$9,345 |
D/D |
10,500 |
10,500 |
0.01 |
- |
|
Culley Brian M |
President and CEO |
|
2024-05-24 |
4 |
B |
$1.05 |
$10,500 |
D/D |
10,000 |
154,842 |
0.01 |
- |
|
Samuel George A. Iii |
General Counsel/Secretary |
|
2024-02-11 |
4 |
D |
$1.08 |
$2,689 |
D/D |
(2,490) |
7,184 |
|
- |
|
Samuel George A. Iii |
General Counsel/Secretary |
|
2024-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,076 |
9,674 |
|
- |
|
Culley Brian M |
President and CEO |
|
2024-02-11 |
4 |
D |
$1.08 |
$13,830 |
D/D |
(12,806) |
144,842 |
|
- |
|
Culley Brian M |
President and CEO |
|
2024-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,249 |
157,648 |
|
- |
|
Bailey Don M |
Director |
|
2024-02-08 |
4 |
B |
$1.04 |
$100,001 |
I/I |
96,155 |
158,801 |
2.1 |
- |
|
Bradsher Neal C |
Director |
|
2024-02-06 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
41,666,255 |
2.17 |
- |
|
Bradsher Neal C |
Director |
|
2024-02-06 |
4 |
B |
$1.04 |
$7,000,001 |
D/D |
6,730,770 |
41,666,255 |
3.92 |
- |
|
Jayasuriya Anula |
Director |
|
2023-12-29 |
4 |
B |
$1.09 |
$10,900 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
Culley Brian M |
President and CEO |
|
2023-02-11 |
4 |
D |
$1.35 |
$17,204 |
D/D |
(12,744) |
126,399 |
|
- |
|
Culley Brian M |
President and CEO |
|
2023-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,249 |
139,143 |
|
- |
|
Hogge Gary S. |
SVP,Clinical & Medical Affairs |
|
2023-02-11 |
4 |
D |
$1.35 |
$7,169 |
D/D |
(5,310) |
7,710 |
|
- |
|
Hogge Gary S. |
SVP,Clinical & Medical Affairs |
|
2023-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,020 |
13,020 |
|
- |
|
Samuel George A. Iii |
General Counsel/Secretary |
|
2023-02-11 |
4 |
D |
$1.35 |
$3,345 |
D/D |
(2,478) |
3,598 |
|
- |
|
173 Records found
|
|
Page 1 of 7 |
|
|